Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Florian G., Granier, Charlène, Zhao, Yuling, Pan, Qi, Tong, Zhichao, Gschwend, Jürgen E., Holm, Per Sonne, Nawroth, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145096/
https://www.ncbi.nlm.nih.gov/pubmed/33923231
http://dx.doi.org/10.3390/jpm11050340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145096/
https://www.ncbi.nlm.nih.gov/pubmed/33923231
http://dx.doi.org/10.3390/jpm11050340

Ejemplares similares